Recursion Pharmaceuticals
RXRX
143 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 62 increasing their positions, 30 reducing their positions, and 19 closing their positions.
107% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 30
55% more call options, than puts
Call options by funds: $266K | Put options by funds: $172K
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
0.86% less ownership
Funds ownership: 68.85% → 67.99% (-0.86%)
2% less funds holding
Funds holding: 146 → 143 (-3)
21% less capital invested
Capital invested by funds: $1.21B → $953M (-$257M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
Kinnevik AB
Stockholm,
Sweden
|
+$75M |
| 2 |
State Street
Boston,
Massachusetts
|
+$32.5M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$31.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.4M |
| 5 |
BlackRock
New York
|
+$8.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$27.9M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$10.1M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.55M |
| 4 |
Lazard Asset Management
New York
|
-$1.38M |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$1.32M |
RXRX Hedge Fund Activity: Q4 2022 in Review
143 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2022, worth a combined $953M — down 21% from $1.21B a quarter earlier.
Fund positioning in RXRX was balanced in Q4 2022: 19 funds opened new positions, 19 closed out, 62 added to existing stakes and 30 trimmed.
The largest buyer was Kinnevik AB, opening a new position worth an estimated $75M. The largest seller was AllianceBernstein, cutting an estimated $27.9M.
- 143 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2022, down from 146 in Q3 2022.
- Funds reported $953M of Recursion Pharmaceuticals stock for Q4 2022, down 21% quarter-over-quarter.
- 19 funds opened new Recursion Pharmaceuticals positions in Q4 2022 and 19 closed out, a net change of 0 holders.
- The largest Recursion Pharmaceuticals buyer in Q4 2022 was Kinnevik AB, an estimated $75M added.
- The largest Recursion Pharmaceuticals seller in Q4 2022 was AllianceBernstein, an estimated $27.9M sold.
Based on aggregated 13F filings for Q4 2022.